Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ) has issued an announcement.
Fuso Pharmaceutical Industries reported non-consolidated net sales of ¥48.27 billion for the nine months ended December 31, 2025, up 3.4% year on year, while operating profit fell 34.8% and profit dropped 29.9%, signaling margin pressure despite modest top-line growth. Total assets increased to ¥89.45 billion and net assets to ¥34.66 billion, but the equity ratio declined from 40.4% to 38.7%, indicating a slightly weaker capital structure.
The company maintained its dividend policy, having paid ¥82 per share in the prior fiscal year and forecasting a higher total dividend of ¥90 per share for the year ending March 31, 2026, underscoring continued shareholder returns. For the full year, Fuso projects modest 1.5% sales growth to ¥61.5 billion but expects double-digit declines in operating and ordinary profit, highlighting ongoing earnings headwinds even as it preserves stable payouts.
The most recent analyst rating on (JP:4538) stock is a Hold with a Yen2482.00 price target. To see the full list of analyst forecasts on Fuso Pharmaceutical Industries,Ltd. stock, see the JP:4538 Stock Forecast page.
More about Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange. The company develops, manufactures, and sells pharmaceutical products, operating under Japanese GAAP accounting standards and targeting the domestic healthcare and medical markets.
Average Trading Volume: 18,196
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen20.66B
For detailed information about 4538 stock, go to TipRanks’ Stock Analysis page.